SIGNIFICANCE OF SINGLE-NUCLEOTIDE POLYMORPHISMS 2578C>A AND +936C>T IN THE VEGF GENE FOR EFFICIENCY EVALUAT ION OF ANTICANCER IMMUNOTHERAPY IN PAT IENTS WITH METASTAT IC SKIN MELANOMA

Abstract. Increased VEGF levels in cancer patients may be associated with decreased number of dendritic cells (DCs) and lower DC function. We investigated whether VEGF gene polymorphisms -2578C>A (rs699947) and +936C>T (rs3025039) are associated with efficacy of autologous DC-based immunotherapy in patients with malignant melanoma. Evaluation of VEGFR-1 and VEGFR-2 expression on mature monocyte-derived DC revealed a decreased VEGFR-1 level (18.9±0.7% on peripheral blood monocytes, as compared to 6.3±0.6% on mature DCs) and non-changed VEGFR-2 expression (13.1±0.4% and 15.9±0.4%, respectively). The АА genotype frequency of -2578C>A (rs699947) polymorphism of VEGF gene was 46.1%. АС heterozygous state was found in 38.5%, and СС, in 15.4% of cases. The VEGF -2578 AC and AA genotypes were directly associated with progression-free survival and efficacy of treatment. The median progression-free survival of patients with -2578 AA and AC genotypes was a significantly longer (8.4 months), as compared with that of patients with CC genotypes (2.7 months), p = 0.002. The established relationship between genotype and efficacy of immunotherapy can be used to develop modern methods for predicting melanoma progression and to personalize immunotherapy including a combination with antiangiogenic therapy.

1. Балдуева И.А., Новик А.В., Моисеенко В.М., Нехаева Т.Л., Данилова А.Б., Данилов А.О., Проценко С.А., Петрова Т.Ю., Улейская Г.И., Щекина Л.А., Семенова А.И., Михайличенко Т.Д., Телетаева Г.М., Жабина А.С., Волков Н.В., Комаров Ю.И. Клиническое исследование (II фаза) вакцины на основе аутологичных дендритных клеток с иммунологическим адъювантом у больных с меланомой кожи // Вопросы онкологии. – 2012. – Т. 58. – С. 212-221. Baldueva I.A., Novik A.V., Moiseenko V.M., Nekhaeva T.L., Danilova A.B., Danilov A.O., Protsenko S.A., Petrova T.Yu., Uleyskaya G.I., Shchekina L.A., Semenova A.I., Mikhaylichenko T.D., Teletaeva G.M., Zhabina A.S., Volkov N.V., Komarov Yu.I. Klinicheskoe issledovanie (II faza) vaktsiny na osnove autologichnykh dendritnykh kletok s immunologicheskim ad»yuvantom u bol`nykh s melanomoy kozhi [The results of second-phase clinical trial of autologous dendritic cells vaccine with immunologic adjuvant in cutaneous melanoma patients]. Voprosy onkologii – Questions of Oncology, 2012, vol. 58, pp. 212-221.

2. Демидов Л.B., Харкевич Г.Ю. Меланома кожи: стадирование, диагностика и лечение // Русский медицинский журнал. – 2003. – №. 1. – С. 112–117. Demidov L.B., Harkevich G.Yu. Melanoma kozhi: stadirovanie, diagnostika i lechenie [Skin Melanoma: staging, diagnostics and treatment]. Russkiy meditsinskiy zhurnal – Russian Medical Journal, 2003, no. 11, pp. 112-117.

3. Михайлова И.Н., Петенко Н.Н., Чкадуа Г.З., Вишнякова Л.Ю. Вакцинотерапия метастатической меланомы с использованием дендритных клеток: клиническое исследование I/II фазы // Российский биотерапевтический журнал. – 2007. – № 6. – С. 39-44. Mikhailova I.N., Petenko N.N., Chkadua G.Z., Vishnyakova L.Yu. Vaktsinoterapiya metastaticheskoy melanomy s ispol`zovaniem dendritnykh kletok: klinicheskoe issledovanie I/II fazy [Dendritic cell vaccine therapy of advanced melanoma: I/II phase clinical trial]. Rossiyskiy bioterapevticheskiy zhurnal – Russian Journal of Biotherapy, 2007, no. 6, pp. 39-44.

4. Чкадуа Г.З., Заботина Т.Н., Буркова А.А., Тамаева З.Э., Огородникова Е.В., Жорданиа К.И., Кадагидзе З.Г., Барышников А.Ю. Адаптирование методики культивирования дендритных клеток человека из моноцитов периферической крови для клинического применения // Российский биотерапевтический журнал. – 2002. – № 3. – С. 56-62. Chkadua G.Z., Zabotina T.N., Burkova A.A., Tamaeva Z.E., Ogorodnikova E.V., Zhordania K.I., Kadagidze Z.G., Baryshnikov A.Yu. Adaptirovanie metodiki kul`tivirovaniya dendritnykh kletok cheloveka iz monotsitov perifericheskoy krovi dlya klinicheskogo primeneniya [The adaptation of method of generating monocyte derived human dendritic cells for clinical practice]. Rossiyskiy bioterapevticheskiy zhurnal – Russian Journal of Biotherapy, 2002, no. 3, pp. 56-62.

5. Alfaro C., Suarez N., Gonzalez A., Solano S., Erro L., Dubrot J., Palazon A., Hervas-Stubbs S., Gurpide A., Lopez-Picazo J.M., Grande-Pulido E., Melero I., Perez-Gracia J.L. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br. J. Cancer, 2009, vol. 100, pp. 1111-1119.

6. Awata T., Kurihara S., Takata N., Neda T., Iizuka H., Ohkubo T., Osaki M., Watanabe M., Nakashima Y., Inukai K., Inoue I., Kawasaki I., Mori K., Yoneya S., Katayama S. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem. Biophys. Res. Commun., 2005, vol. 333, pp. 679-685.

7. Dikov M.M., Ohm J.E., Ray N., Tchekneva E.E., Burlison J., Moghanaki D., Nadaf S., Carbone D.P. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J. Immunol., 2005, vol. 174, pp. 215-222.

8. Eubank T.D., Roberts R., Galloway M., Wang Y., Cohn D.E., Marsh C.B. GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice. Immunity, 2004, vol. 21, pp. 831-842.

9. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer, 2002, vol. 2, pp. 795-803.

10. Hamai A., Benlalam H., Meslin F., Hasmim M., Carré T., Akalay I, Janji B., Berchem G., Noman M.Z., Chouaib S. Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune? Tissue Antigens, 2010, vol. 75, pp. 1-8.

11. Han S.W., Kim G.W., Seo J.S., Kim S.J., Sa K.H., Park J.Y., Lee J., Kim S.Y., Goronzy J.J., Weyand C.M., Kang Y.M. VEGF gene polymorphisms and susceptibility to rheumatoid arthritis. Rheumatology, 2004, vol. 43, pp. 1173-1177.

12. Hayashi T., Hideshima T., Akiyama M., Raje N., Richardson P., Chauhan D., Anderson K.C. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood, 2003, vol. 102, pp. 1435-1442.

13. Mimura K., Kono K., Takahashi A., Kawaguchi Y., Fujii H. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol Immunother., 2007, vol. 56, pp. 761-770.

14. Nasr H.B., Chahed K., Bouaouina N., Chouchane L. Functional vascular endothelial growth factor −2578 C/A polymorphism in relation to nasopharyngeal carcinoma risk and tumor progression. Clinica Chimica Acta, 2008, vol. 395, pp. 124-129.

15. Renner W., Kotschan S., Hoffmann C., Obermayer-Pietsch B., Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J. Vasc. Res., 2000, vol. 37, no. 6, pp. 443-448.

16. Salven P., Heikkilä P., Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br. J. Cancer, 1997, vol. 76, pp. 930-934.

17. Steffensen K.D., Waldstrom M., Brandslund I., Jakobsen A. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecologic Oncology, 2010, vol. 117, pp. 109-116.

18. Steinman RM. Dendritic cells in vivo: a key target for a new vaccine science. Immunity, 2008. vol. 29, pp. 319-324.

19. Yang Z.F., Poon R.T., Luo Y., Cheung C.K., Ho D.W., Lo C.M., Fan S.T. Up-regulation of vascular endothelial growth factor (VEGF) in small-for-size liver grafts enhances macrophage activities through VEGF receptor 2-dependent pathway. J. Immunol, 2004, vol. 173, pp. 2507-2515.